220 related articles for article (PubMed ID: 15105056)
1. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
Strom BL; Berlin JA; Weber AL; Norman SA; Bernstein L; Burkman RT; Daling JR; Deapen D; Folger SG; Malone KE; Marchbanks PA; Simon MS; Ursin G; Weiss LK; Spirtas R
Contraception; 2004 May; 69(5):353-60. PubMed ID: 15105056
[TBL] [Abstract][Full Text] [Related]
2. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
van Leeuwen FE
Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
[TBL] [Abstract][Full Text] [Related]
3. Risk of breast cancer associated with short-term use of oral contraceptives.
Folger SG; Marchbanks PA; McDonald JA; Bernstein L; Ursin G; Berlin JA; Daling JR; Norman SA; Strom BL; Weiss LK; Simon MS; Burkman RT; Malone KE; Spirtas R
Cancer Causes Control; 2007 Mar; 18(2):189-98. PubMed ID: 17216547
[TBL] [Abstract][Full Text] [Related]
4. Researchers can now investigate long-term effects of OCs on cancer.
Rubin GL; Peterson HB
Contracept Technol Update; 1985 Jan; 6(1):7-12. PubMed ID: 12279918
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Results of an international, multicenter, case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Contraception; 1998 May; 57(5):315-24. PubMed ID: 9673838
[TBL] [Abstract][Full Text] [Related]
7. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
8. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.
Anderson GL; Chlebowski RT; Rossouw JE; Rodabough RJ; McTiernan A; Margolis KL; Aggerwal A; David Curb J; Hendrix SL; Allan Hubbell F; Khandekar J; Lane DS; Lasser N; Lopez AM; Potter J; Ritenbaugh C
Maturitas; 2006 Sep; 55(2):103-15. PubMed ID: 16815651
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
[TBL] [Abstract][Full Text] [Related]
10. At pill's 30th birthday, breast cancer question is unresolved.
Althaus FA; Kaeser L
Fam Plann Perspect; 1990; 22(4):173-6. PubMed ID: 2226748
[TBL] [Abstract][Full Text] [Related]
11. Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population.
Kerlikowske K; Miglioretti DL; Ballard-Barbash R; Weaver DL; Buist DS; Barlow WE; Cutter G; Geller BM; Yankaskas B; Taplin SH; Carney PA
J Clin Oncol; 2003 Dec; 21(23):4314-21. PubMed ID: 14645420
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of oral contraceptives and the risk of breast cancer.
Webster L
J Reprod Med; 1986 Jun; 31(6 Suppl):540-5. PubMed ID: 3723486
[TBL] [Abstract][Full Text] [Related]
13. Menstrual factors in relation to breast cancer risk.
Titus-Ernstoff L; Longnecker MP; Newcomb PA; Dain B; Greenberg ER; Mittendorf R; Stampfer M; Willett W
Cancer Epidemiol Biomarkers Prev; 1998 Sep; 7(9):783-9. PubMed ID: 9752986
[TBL] [Abstract][Full Text] [Related]
14. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
[TBL] [Abstract][Full Text] [Related]
15. Exogenous progestins and breast cancer.
Stanford JL; Thomas DB
Epidemiol Rev; 1993; 15(1):98-107. PubMed ID: 8405216
[TBL] [Abstract][Full Text] [Related]
16. Hormone replacement therapy use and variations in the risk of breast cancer.
Opatrny L; Dell'Aniello S; Assouline S; Suissa S
BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
[TBL] [Abstract][Full Text] [Related]
17. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones.
Tworoger SS; Missmer SA; Barbieri RL; Willett WC; Colditz GA; Hankinson SE
J Natl Cancer Inst; 2005 Apr; 97(8):595-602. PubMed ID: 15840882
[TBL] [Abstract][Full Text] [Related]
18. Oral contraceptives and breast cancer. A meta-analysis.
Delgado-Rodriguez M; Sillero-Arenas M; Rodriguez-Contreras R; López Gigosos R; Gàlvez Vargas R
Rev Epidemiol Sante Publique; 1991; 39(2):165-81. PubMed ID: 1830968
[TBL] [Abstract][Full Text] [Related]
19. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
20. Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study.
Lee E; Ma H; McKean-Cowdin R; Van Den Berg D; Bernstein L; Henderson BE; Ursin G
Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3170-8. PubMed ID: 18990759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]